NCT05076422

A Study to Test How Well Men Tolerate Different Doses of BI 3006337

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Subcutaneous Doses of BI 3006337 in Healthy Male Subjects (Single-blind, Partially Randomised Within Dose Groups, Placebo-controlled, Parallel (Sequential) Group Design)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics of BI 3006337 in healthy male subjects following subcutaneous administration of single-rising doses.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	BI 3006337	BI 3006337
DRUG	Placebo	Placebo

Timeline

• Start date: 2021-10-18
• Primary completion: 2023-03-03
• Completion: 2023-03-03
• First posted: 2021-10-13
• Last updated: 2026-01-08
• Results posted: 2026-01-08

Locations

2 sites across 2 countries: Belgium, Netherlands